Testing new cancer treatments on cells from ovarian cancer fluid
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This laboratory study uses ovarian cancer fluid collected during surgery to test possible new treatments on cancer and immune cells. It may help researchers find better treatment options in ovarian cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older having surgery to remove ovarian cancer tissue
- Doctors suspect ovarian (or related) cancer and surgery is planned for tumor removal
- Your cancer type must be epithelial ovarian cancer (including fallopian tube or primary peritoneal cancer)
- If you could become pregnant, your pregnancy test must be negative within 2 weeks before the study
- You must be able to read, understand, and sign the consent form yourself
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at fluid from the belly (ascites) in people with ovarian cancer to understand it better. It only includes women who are having surgery to remove as much cancer as possible.
This study uses lab testing to create a “map” of ovarian cancer cells one cell at a time, to better understand the disease. It likely helps researchers learn which cell types are involved, using samples collected around your surgery.
This study is testing a new blood test that may help detect ovarian cancer earlier. Researchers want to see if it can tell the difference between people with ovarian cancer and those without it.
This trial tests a new approach using your own immune cells (tumor-infiltrating lymphocytes) that have been modified to work better, followed by a combination of oral chemo and immunotherapy. It's for people with ovarian cancer that has come back after standard treatment.
This Phase 1 study tests whether giving your own immune cells—engineered to target the FSH receptor—can control recurrent ovarian-related cancers. It’s mainly looking at safety and early signs of activity for patients whose cancer has not responded well to standard platinum chemotherapy.
This study is testing a blood test to see if it can catch ovarian cancer early. You may be eligible if you have been recently diagnosed with ovarian cancer and haven't started treatment yet.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.